0001469443-26-000002.txt : 20260626 0001469443-26-000002.hdr.sgml : 20260626 20260626165218 ACCESSION NUMBER: 0001469443-26-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260626 DATE AS OF CHANGE: 20260626 EFFECTIVENESS DATE: 20260626 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arcadia Biosciences, Inc. CENTRAL INDEX KEY: 0001469443 STANDARD INDUSTRIAL CLASSIFICATION: CRUDE PETROLEUM & NATURAL GAS [1311] ORGANIZATION NAME: 01 Energy & Transportation EIN: 810571538 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-588846 FILM NUMBER: 261130142 BUSINESS ADDRESS: STREET 1: 5956 SHERRY LANE STREET 2: SUITE 2000 CITY: DALLAS STATE: TX BUSINESS PHONE: 214-974-8921 MAIL ADDRESS: STREET 1: 5956 SHERRY LANE STREET 2: SUITE 2000 CITY: DALLAS STATE: TX D 1 primary_doc.xml X0708 D LIVE 0001469443 Arcadia Biosciences, Inc. 5956 SHERRY LANE SUITE 2000 DALLAS TX TEXAS 75225 214-974-8921 DELAWARE None None Corporation true Thomas J. Schaefer 5950 Sherry Lane Suite 2000 Dallas TX TEXAS 75225 Executive Officer Director Kevin Comcowich 5950 Sherry Lane Suite 2000 Dallas TX TEXAS 75225 Director Amy Yoder 5950 Sherry Lane Suite 200 Dallas TX TEXAS 75225 Director Lilian Shackelford Murray 5950 Sherry Lane Suite 2000 Dallas TX TEXAS 75225 Director Gregory D Waller 5950 Sherry Lane Suite 200 Dallas TX TEXAS 75225 Director Other Technology Decline to Disclose 06b false 2026-06-12 false true true true false 0 H.C. Wainwright & Co, LLC 375 None None 430 Park Avenue New York NY NEW YORK 10022 NY NEW YORK false 11417964 3999613 7418351 Includes gross proceeds received from issuance of pre-funded warrants & preferred investment options. Offering also reflects the aggregate exercise price of pre-funded warrants, preferred investment options and placement agent investment options issued. false 5 395000 0 In addition to cash fee, the company paid certain expenses of $75,000 and issued placement agent preferred investment options to purchase up to 271,845 shares of common stock at exercise price $1.2875 per share. 0 false Arcadia Biosciences, Inc. Thomas J. Schaefer Thomas J. Schaefer CEO 2026-06-18